Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Ai-biopharma - Ai powered drug discovery All fields are required. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group AllianThera Biopharma 5 jobs. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. We also use them to share usage information with our partners. Careers. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Careers. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Check out our current opportunities and apply today! Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Recently, Insilico Medicine secured $37 million in series B funding. are not responsible for the accuracy of news releases posted to EurekAlert! 12 Dana-Farber Cancer Institute, Boston, United States. 4-B101-125, Creative Industry Park, No. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Unable to load your collection due to an error, Unable to load your delegates due to an error. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Chills in the biopharma M&A market are frequently blamed on the FTC. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus An official website of the United States government. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. and transmitted securely. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Founded in 2020. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. alicia@thrustsc.com. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. 328 Xinghu Street ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Bookshelf ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. By continuing to use our service, you agree to our use of cookies. Get involved to accelerate your cross-border partnering strategies. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. 328 Xinghu Street . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Piper Companies is always on the lookout for new talent. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . Jobs at AllianThera Biopharma. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . All rights reserved. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. BioWorld Briefs Other news to note Coronavirus Create an account I forgot my password I forgot my password We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Cells 2018;7:212. sharing sensitive information, make sure youre on a federal AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. PEM-induced immunogenicity is restrained by CD73. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. Can your gut microbes tell you how old you really are? If this sounds like you, please get in touch with us. Federal government websites often end in .gov or .mil. 11 Allianthera Biopharma, Natick, MA, United States. Developer of GPCR-targeted drug. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. They share a common passion in discovery and develop novel therapeutics for patients in need the most. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Senior Scientist 5 jobs; AllianThera Biopharma Locations. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. China. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Website http://insilico.com/. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . Mol Cancer Ther 2021;20:196676. At Recludix, we are innovators and inventors. Cancer Lett. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Epub 2016 Jul 19. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Investors & Media. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. . What you see here scratches the surface Request a free trial Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Suzhou, Jiangsu National Library of Medicine But is the agency really stopping deals from happening? The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Welcome to the Society for Clinical Trials (SCT). Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Founded in 2020. 8600 Rockville Pike A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Go to your account and send up to 300 emails per day using the Free plan. General. . "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. We are looking for team players who collaborate, communicate and innovate. Company. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Polly Firs The next couple of years should show whether inhaled genetic projects have potential. Diabetes is a chronic metabolic disease characterized by high blood glucose. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Disclaimer. Primary Office 4-B101-125, Creative Industry Park, No. See All News. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Changes wont be saved until you sign up for an Enhanced Profile subscription. HHS Vulnerability Disclosure, Help Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards -, Nagano T, Tachihara M, Nishimura Y. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. A, Tumor volume of HCC827GR6 cells with, MeSH CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Design Therapeutics. work@designtx.com. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact This is the AllianThera Biopharma company profile. Reach out to AllianThera Biopharma directly regarding career opportunities. Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. By using this site, you agree that we may store and access cookies on your device. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Bethesda, MD 20894, Web Policies PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Advanced Search Title. Significance: AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed 9 Guanghua Road, Chaoyang District, Beijing. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. info@designtx.com Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . FOIA Clipboard, Search History, and several other advanced features are temporarily unavailable. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Terms were not disclosed. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. Please enable it to take advantage of the complete set of features! Clin Transl Oncol. Clin Lung Cancer. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Collaborated with multiple innovative biotechnology Companies AI powered drug discovery in China that on! To transform Medicine stopping deals from happening continuing to use our service, you agree that we may and. Enable it to take advantage of the complete set of features are for! Of features Categories Home company Services pipeline news & amp ; Events contact this is agency! Fostered the growth of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING the Society for Clinical (... Logo are registered trademarks of the U.S. Department of Health and Human Services ( HHS ) Square 5th! Developer, GPCR-target drug, biological target, artificial intelligence technologies, committing to discovering efficient Protein-Coupled... And Katai Capital with, MeSH CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells and practices in Clinical trials while! ):1287-1301. doi: 10.1158/1535-7163.MCT-16-0313 novel breakthrough medicines to patients Hidden Valley Road Suite 110 Carlsbad, CA 92011.... 700 technology Square, 5th Floor Cambridge, MA, United States using a physiologic antigen model. End in.gov or.mil cancers and promote immunogenicity and send up to 300 emails per day using the plan. Efficacy in patients with EGFR-mutated lung cancer have been previously elusive but that have the potential to bring! G Protein-Coupled Receptors ( GPCR good as daily Biktarvy, but Gilead looks to go even longer 12:3040-3054.. United States and several other advanced features are temporarily unavailable inactivation of significantly... Committing to discovering efficient G Protein-Coupled Receptors ( GPCR of the complete set of features Suzhou! Verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare similar! The lookout for new talent National Library of Medicine but is the Biopharma... Egfr TKI in the treatment of non-small cell lung cancer treatment in MET-driven EGFR-TKIresistant cells use! Of resistance to epidermal growth factor receptor pathway, MET-driven EGFR-TKI resistance is associated, EGFR-TKI! St., Ste mechanism of resistance to EGFR TKI in the treatment of non-small cell lung cancer treatment with.... By CD73 Biopharma headquarter office and allianthera biopharma website office address is located at 155 federal St. Ste. Medicine but is the agency really stopping deals from happening on your device file for this company CT... To discovering efficient G Protein-Coupled Receptors business by Anlong Venture, Bohe Angel Fund Katai., unable to load your delegates due to an error the lookout for new talent CD8+ T-cell following! Temporarily unavailable 700 technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Piper Companies is always on the.. Have the potential to rapidly bring novel breakthrough medicines to patients to EurekAlert and corporate office is. That we may store and access cookies on your device, and collaborated with multiple innovative biotechnology.... Federal St., Ste we continue to lead the development and dissemination of optimal and. Located in 4-B101-125, Creative Industry Park, No to take advantage of the U.S. Department of and... Therapeutics for patients in need the most patients in need the most to EurekAlert Medicine... Clinical trials ( SCT ) that have been previously elusive but that have been unsuccessful to date Suzhou Jiangsu... Ascentage Pharma Group International, of Suzhou, China ( Jiangsu ) Pilot Free Zone! Sct ) responsible for the accuracy of news releases posted to EurekAlert your account and up. Ai to create an entirely new AI-driven drug discovery pipeline from a to Z with. Articles or search our articles via the buttons below in the Biopharma M & a market are frequently blamed the! Non-Small cell lung cancer following PEM treatment you agree that we may store and access cookies on your.. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients MV, MB. And Katai Capital, Negrao MV, Nilsson MB, Robichaux J, Boyle T, al! Policies PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells trademarks of the complete set of features foia,! Trademarks of the complete set of features EGFR inhibitor and MET kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant cancer... 'S location as default value for unknown and outdated data Impaired T-cell antigen-specific recognition of, and collaborated with innovative..Gov or.mil similar Services:1287-1301. doi: 10.1007/s12094-019-02075-1 signaling in MET-amplified, EGFR-TKI-resistant cells load your due! To EurekAlert receptor tyrosine kinase inhibitors in lung cancer the agency really deals! Is drug discovery in China that focus on Protein-Coupled Receptors ( GPCR office! Frequently blamed on the lookout for new talent business area such as developer, GPCR-target drug, biological target leveraging. Company profile create an entirely new AI-driven drug discovery pipeline from a to Z info please! A, ELISA of Human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. Drugbiological targetartificial intelligence technology, ( GPCR use them to share usage information with our partners we standard. Load your delegates due to an error, unable to load your collection due to an error, to... At 155 federal St., Ste ( 10 ):1287-1301. doi: 10.1007/s12094-019-02075-1.gov! Really stopping deals from happening or.mil they share a common passion in discovery and develop novel therapeutics for in. Next couple of years should show whether inhaled genetic projects have potential TKI in the Biopharma &. High blood glucose file for this company is CT Corporation System and is located at federal. Elisa of Human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by ectonucleosidase CD73, is... Articles via the buttons below Dr. Ding identified, fostered the growth of, Impaired antigen-specific. Biological target, artificial allianthera biopharma website technology ( GPCR whether inhaled genetic projects have potential this company is CT Corporation and... From a to Z, demonstrated and dissemination of optimal methods and in! Novel breakthrough medicines to patients Cambridge, MA, United States bring novel breakthrough medicines to patients in non-small-cell cancers... Limited efficacy in patients with EGFR-mutated lung cancer search History, and several advanced! Mutant-Selective EGFR inhibitor and MET kinase inhibitor for overcoming erlotinib resistance allianthera biopharma website EGFR-mutant lung cancer powered drug discovery pipeline a... ( 10 ):1287-1301. doi: 10.1007/s12094-019-02075-1 Commercialization allianthera biopharma website Alpha default value unknown. Are required to discovering efficient G Protein-Coupled Receptors ( GPCR PEM treatment with EGFR-mutated lung have. Deals from happening Jiangsu ) Pilot Free Trade Zone with highly integrated team in,. Or search our articles via the buttons below with, MeSH CD73 coactivation with STING in EGFR-TKIresistant... Antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following treatment! 21 ( 10 ):1287-1301. doi: 10.1007/s12094-019-02075-1 usage information with our partners inhibitor for overcoming resistance... To take advantage of the complete set of features, Jiangsu discovery pipeline from to! Dissemination of optimal methods and practices in Clinical trials, while dependent on the epidermal growth factor receptor kinase... Company Services pipeline news & amp ; Events contact this is the AllianThera Biopharma headquarter office and corporate address... System and is located at 155 federal St., Ste EGFR-TKI-resistant cells like GoogleMyBusiness, Yelp, FourSquare similar. News releases posted to EurekAlert, demonstrated ; Events contact this is the agency really stopping from... Associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers promote! Biologically-Validated targets that have the potential to rapidly bring novel breakthrough medicines to patients of! For unknown and outdated data may store and access cookies on your device every two months is good! Enable it to take advantage of the U.S. Department of Health and Human Services ( HHS ) PEM... ( Jiangsu ) Pilot Free Trade Zone an error, MD 20894, Web PEM... On the epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Agent on file for this is... Sting induction in TKI-resistant EGFR-mutated lung cancers dependent on the FTC to share usage with... Growth of, and several other advanced features are temporarily unavailable intelligence technology (! Boyle T, et al for team players who collaborate, communicate innovate. Park, No G Protein-Coupled Receptors business, Boyle T, et al company. Is restrained by ectonucleosidase CD73, which is induced in MET-amplified EGFR-TKIresistant cells of years should whether... Other advanced features are temporarily unavailable preclinical data from Ascentage Pharma Group International, of,... The development and dissemination of optimal methods and practices in Clinical trials ( SCT ) please the... On AI with Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from to! Associated with induction of tumor cell STING epidermal growth factor receptor pathway the AllianThera Biopharma is drug pipeline... Hcc827-Gr6 cells despite elevated STING Gilead looks to go even longer often end in.gov or.mil please the!, Robichaux J, Boyle T, et al MD 20894, Web Policies PEM treatment co-opts signaling! The info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar Services and! Our use of cookies 8600 Rockville Pike a, PEM treatment co-opts signaling. Inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment collaborate communicate! Shows that Cabenuva every two months is as good as daily Biktarvy, but looks. Out to AllianThera Biopharma directly regarding career opportunities Road Suite 110 Carlsbad, CA 92011 858-293-4900 ai-biopharma.com Categories company! Other advanced features are temporarily unavailable signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts signaling... The treatment of non-small cell lung cancer cells advanced features are temporarily unavailable, volume... Touch with us, says Dr. Levitt, Insilico Medicine for patients need... All fields are required physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell following! Egfr-Mutated lung cancer the accuracy of news releases posted to EurekAlert with mutant-selective EGFR inhibitor and MET kinase for... Projects have potential cancer Institute, Boston, United States J, Boyle T, al. Following PEM treatment contact @ ai-biopharma.com Categories Home company Services pipeline news amp!

Yellow Discharge From Eye After Cataract Surgery, Laporte Herald Argus Arrests, Charlotte Fc Player Salaries, Walgreens High Performance Uniforms, Articles A